Download

Download the National Bloood Authority Annual Report 2011–12 in Adobe PDF format (5.7MB).

Get Adobe Reader

With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under a Creative Commons Attribution 3.0 Australia licence.

The details of the relevant licence conditions are available on the Creative Commons website (accessible using the links provided) as is the full legal code for the CC BY 3.0 AU licence.

The content obtained from this document or derivative of this work must be attributed as the National Blood Authority annual report 2011–12.

ISSN 1832-1909

Web address of this report: www.nba.gov.au/pubs/annual-report.htm

Printed by: Paragon Printers Australasia

Designed by: Swell Design Group

Contact officer: Rachel Wright
Communications Manager

Locked Bag 8430
Canberra ACT 2601
Telephone: 02 6211 8300
Facsimile: 02 6211 8330
Email: nba@nba.gov.au
Website: www.nba.gov.au

• Blood sector governance
• NBA role and responsibilities
• Blood products and how they are used
• The Australian blood supply chain
• Blood sector funding

• Snapshot of the blood sector in 2011–12
• General Manager’s review
• NBA Board and report

• Introduction
• The annual National Supply Plan and Budget (nsp&b)
• Managing blood supply contracts and arrangements
• Evaluation methodologies for change proposals

• Introduction
• Sector improvement
• Management of risk

• Introduction
• National guidelines and criteria for use
• Standards, accreditation and stewardship
• Education
• Clinical governance and data systems
• Networks and communication
• Quality improvement initiatives

• Governance
• Planning and service delivery
• People management

• Budget and financial management
• Purchasing
• Asset management
• Financial statements

• A1 Blood sector stakeholders and governance
• A2 The National Blood Agreement: objectives of governments
• A3 NBA Agency Resource Statement
• A4 NBA Board Members
• A5 Fresh blood components supplied under contract by the blood service 2011–12
• A6 Plasma and recombinant products supplied under contract in 2011–12
• A7 Units of red cells, platelets and IVIg issued per 1000 head of population by state and territory 2007–08 to 2011–12
• A8 Responsibility and composition of governance committees
• A9 Mandatory reporting
• A10 Errata
• A11 Glossary of terms and acronyms
• A12 List of requirements

• 1.1 Government funding to the NBA for the supply of blood and blood products, 2003-04 to 2011-12
• 1.2 Government funding for the operation of the NBA, 2003-04 to 2011-12
• 3.1 Blood and blood products purchased, by suppliers, 2008-09 to 2011-12
• 3.2 Variance between actual supply of fresh blood components against the annual supply estimates, 2011-12
• 3.3 Annual expenditure: Blood Service, 2003-04 to 2011-12
• 3.4 Blood Service: selected key performance indicators, 2011-12
• 3.5 Blood Service: plasma volumes collected for fractionation (tonnes), 2003-04 to 2011-12
• 3.6 Red cell age at issue by quarter, 2010-11 to 2011-12
• 3.7 Blood Service annual capital plan: actual expenditure, 2007-08 to 2011-12
• 3.8 Annual expenditure on plasma fractionation: CSL Limited, 2003-04 to 2011-12
• 3.9 CSL Limited's actual performance under the CAFA, 2011-12
• 3.10 Imported IVIg: key performance indicators, by supplier, 2011-12
• 3.11 Octapharma Australia: key performance indicators, 2010–11
• 3.12 Imported plasma and recombinant blood product contracts: key performance indicators, by supplier, 2011-12
• 4.1 Implementation of BloodNet modules, by state and territory, at 30 June 2012
• 6.1 NBA's performance in achieving objectives of its operational plans, 2007-08 to 2011-12
• 6.2 Number of NBA staff at 30 June 2012
• 6.3 Numbers of NBA staff on types of employment agreements
• 6.4 Salary levels of NBA staff at 30 June 2012
• 7.1 Overall funding and expenditure for the NBA in 2011–12: a summary
• 7.2 Key results in financial performance, 2008-09 to 2011-12
• 7.3 Administered revenue, 2008-09 to 2011-12
• 7.4 Key results of administered expenses, 2008-09 to 2011-12
• 7.5 Expenditure on consultancy services, 2008-09 to 2011-12

• 1.1 Governance structure of the Australian blood sector
• 1.2 The blood product family
• 1.3 The Australian blood and blood products supply chain
• 3.1 Expenditure by product category 2011-12
• 3.2 Actual issues performance against the NSP&B and mid-year review, 2008-09 to 2011-12
• 3.3 Fresh blood expenditure: increases on 2003-04 base year
• 3.4 Red cells issued by the Blood Service, 2007-08 to 2011-12
• 3.5 Red cells issued per 1000 head of population, 2007-08 to 2011-12
• 3.6 Platelets issued by the Blood Service, 2007-08 to 2011-12
• 3.7 Platelets issued per 1000 head of population, 2007-08 to 2011-12
• 3.8 Plasma-derived and overseas product expenditure: cumulative increases on 2003-04 base year
• 3.9 Issues of Factor VIII products, 2007-08 to 2011-12
• 3.10 Issues of total Factor VIII per 1000 head of population, 2007-08 to 2011-12
• 3.11 Market share of recombinant Factor VIII issues, 2007-08 to 2011-12
• 3.12 Issues of Factor IX products, 2007-08 to 2011-12
• 3.13 Issues of Factor IX products per 1000 head of population, 2007-08 to 2011-12
• 3.14 Issues of recombinant Factor VIIa, 2007-08 to 2011-12
• 3.15 Issues of FEIBA, 2007-08 to 2011-12
• 3.16 Issues of IVIg products, 2007-08 to 2011-12
• 3.17 Issues of IVIg (grams) per 1000 head of population, 2007-08 to 2011-12
• 3.18 Top ten uses of IVIg, 2008-09 to 2011-12
• 3.19 Issues of NIg, 2007-08 to 2011-12
• 3.20 Red blood cell days of inventory at the Blood Service, of major blood type, by business day, 2010-11 to 2011-12
• 3.21 Market share for suppliers of diagnostic reagent products, 2007-08 to 2011-12
• 4.1 ABDR haemophilia treatment centre dashboard report
• 5.1 Framework for supporting appropriate and safe use of blood and blood products
• 6.1 NBA's governance structure at 30 June 2012
• A7.1 ABDR haemophilia treatment centre dashboard report
• A7.2 Framework for supporting appropriate and safe use of blood and blood products
• A7.3 NBA's governance structure at 30 June 2012